Medigen Biotechnology Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medigen Biotechnology Corp.
Exec Chat: Medtronic’s Linnea Burman Targets 'Consensus-Driven Care' Using AI, Robotics In Spine Care
Linnea Burman, the general manager of enabling technologies for cranial and spinal technologies at Medtronic, talked to Medtech Insight about plans for the Mazor spinal robotic system, the incoming new president of the division, and other new developments.
A new global clinical trial initiative is assessing a number of second-generation candidate vaccines for COVID-19. The Australian medicines regulator has given the go-ahead for an approval application for one of the vaccines, from Taiwan’s Medigen.
The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.
In a series on articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are six new anti-infectives expected to reach the market for the first time next year, all with an above average likelihood of approval.
- Other Names / Subsidiaries
- Medigen Vaccine Biologics Co.
- Medigen Vaccinology Corp.